Altair Therapeutics Receives $17,000,000 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1a36ca1d-10d3-48f5-9dda-6c9dd154ade4&Preview=1 -
Date
11/12/2009 -
Company Name
Altair Therapeutics -
Mailing Address
12555 High Bluff Drive San Diego, CA 92130 -
Company Description
Altair is building a dedicated team, combining antisense drug discovery expertise with respiratory drug development expertise, to focus solely on the development and commercialization of antisense drugs for the treatment of asthma and other respiratory conditions. -
Website
http://www.altairtherapeutics.com -
Transaction Type
Venture Equity -
Transaction Amount
$17,000,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Altair Therapeutics will use the funding to complete phase 2a trials for its lead product, inhaled AIR645 and advance research and development in new target programs. -
M&A Terms
-
Venture Investor
Domain Associates -
Venture Investor
Thomas, McNerny & Partners -
Venture Investor
Forward Ventures -
Venture Investor
Isis Pharmaceuticals -
Venture Investor
Undisclosed
